European commission approves seagen's tukysa® (tucatinib) for the treatment of patients with locally advanced or metastatic her2-positive breast cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced that the european commission (ec) has granted marketing authorization for tukysa® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-her2 treatment regimens. tukysa is an oral, small molecule tyrosine kinase inhibitor (tki) of her2, a protein that contributes to cancer ce
SGEN Ratings Summary
SGEN Quant Ranking